A plasmacytoma is a tumor composed of a single abnormal clone of plasma cells, the immune cells that normally produce antibodies. It most often develops in bone, but it can also arise in soft tissue. A solitary plasmacytoma is a localized plasma-cell cancer without the systemic findings required for a diagnosis of multiple myeloma. Distinguishing localized disease from myeloma is central to classification, treatment, and prognosis.
Types and terminology
Two principal forms of solitary plasmacytoma are recognized:
- Solitary bone plasmacytoma arises within bone, commonly in the vertebrae, pelvis, ribs, or skull. It usually produces a destructive, or lytic, bone lesion and may extend into adjacent soft tissue.
- Extramedullary plasmacytoma, also called extraosseous plasmacytoma, arises in soft tissue rather than bone. The upper respiratory tract, including the nasal cavity, paranasal sinuses, and nasopharynx, is a frequent location, although other organs can be affected.
A bone tumor extending directly into surrounding soft tissue remains a bone plasmacytoma rather than a primary extramedullary tumor.
The term plasmacytoma can also describe a localized mass in someone who has multiple myeloma. Such a mass is not classified as solitary plasmacytoma because it forms part of systemic disease.
Within solitary disease, a distinction is made between cases with no detectable clonal plasma cells in otherwise uninvolved bone marrow and cases with minimal marrow involvement, in which clonal plasma cells constitute less than 10% of marrow cells. Minimal marrow involvement is associated with a greater risk of progression to myeloma.
Biology and occurrence
Normal plasma cells are differentiated B lymphocytes involved in antibody production. In plasmacytoma, an abnormal clone accumulates in a localized site. The tumor cells may produce a monoclonal immunoglobulin, often called an M protein, or free immunoglobulin light chains that can be detected in blood or urine. Some tumors produce no measurable circulating monoclonal protein.
Plasmacytoma is uncommon and occurs predominantly in adults, particularly older adults. It is diagnosed more often in men than in women. Its cause is generally unknown, and no single exposure accounts for most cases.
Clinical features
Symptoms depend on the tumor’s location and its effects on nearby structures.
Bone plasmacytoma commonly causes localized pain. Destruction of bone can produce a fracture with little or no preceding trauma. Vertebral lesions may cause collapse or compression of the spinal cord or nerve roots, leading to weakness, altered sensation, or impaired movement.
Extramedullary tumors may present as a visible or palpable mass. Tumors in the upper respiratory tract can cause nasal obstruction, nosebleeds, difficulty swallowing, or changes in voice.
Widespread bone lesions, otherwise unexplained anemia, impaired kidney function, or elevated blood calcium attributable to the plasma-cell disorder raise concern for multiple myeloma rather than an isolated tumor.
Diagnosis and staging
Diagnosis requires both identification of the tumor and assessment of whether disease is truly localized.
Tissue examination
A biopsy demonstrates an accumulation of clonal plasma cells. Histopathological examination and immunophenotyping establish the cells’ identity and distinguish the tumor from other malignancies, including some forms of lymphoma. Restriction to one immunoglobulin light-chain type—kappa or lambda—supports clonality.
Evaluation for systemic disease
The assessment generally includes:
- A bone marrow aspirate and biopsy to measure plasma-cell involvement and identify abnormal cells.
- Blood counts, calcium measurement, and tests of kidney function.
- Serum and urine studies for monoclonal proteins, including immunofixation and serum free light-chain testing.
- Imaging to identify additional bone or soft-tissue lesions.
Magnetic resonance imaging, whole-body low-dose computed tomography, and positron emission tomography combined with CT have complementary roles. Imaging can reveal lesions not apparent on conventional radiographs and can assess local extension.
A diagnosis of solitary plasmacytoma requires a single proven lesion, no additional lesions on appropriate imaging, and no myeloma-defining systemic findings. A small monoclonal protein may be present and does not by itself establish multiple myeloma. Conversely, the absence of an M protein does not exclude plasmacytoma.
Treatment
Radiation therapy is the principal treatment for most solitary plasmacytomas because plasma-cell tumors are generally radiosensitive. Its purpose is durable control of the localized lesion.
Surgery has a role in obtaining diagnostic tissue, stabilizing damaged bone, relieving neurological compression, or removing selected soft-tissue tumors. Radiotherapy may still be used after an operation.
Routine systemic chemotherapy is not established as standard treatment for all patients with truly solitary disease. Systemic treatment becomes relevant when the findings meet criteria for multiple myeloma. The role of additional drug therapy in selected higher-risk solitary cases remains under investigation.
Course and follow-up
Local tumor control is often achievable, but some patients subsequently develop multiple myeloma. Progression is more frequent after solitary bone plasmacytoma than after primary extramedullary plasmacytoma. Risk is also higher when sensitive testing detects clonal plasma cells in otherwise uninvolved marrow.
Persistent monoclonal protein after treatment and an abnormal serum free light-chain ratio can provide prognostic information. These findings require interpretation alongside imaging, marrow findings, and other laboratory results rather than being treated as proof of progression in isolation.
Long-term follow-up assesses local recurrence and the development of systemic disease through clinical examination, laboratory testing, and imaging when indicated. Disappearance or control of the original mass does not eliminate the possibility of later myeloma.